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Abstract
High-dose melphalan with autologous stem cell transplantation (ASCT) can induce durable haematological and organ
responses in systemic AL amyloidosis (AL). Stringent selection criteria have improved safety of ASCT in AL but most
patients are transplant-ineligible. We report our experience of deferred ASCT in AL patients who were transplant-
ineligible at presentation but had improvements in organ function after induction chemotherapy, enabling them to
undergo ASCT. Twenty-two AL patients underwent deferred ASCT from 2011 to 2017. All had serial organ function and
clonal response assessment. Organ involvement and responses were deﬁned by amyloidosis consensus criteria. All
patients were transplant-ineligible at presentation, predominantly due to advanced cardiac involvement. All received
bortezomib-based therapy, with 100% haematologic response (86% complete response (CR)/very good partial
response (VGPR)), enabling reversal of ASCT exclusion criteria. Patients underwent deferred ASCT for haematologic
progression (45%) or consolidation (55%). There was no transplant-related mortality. Haematologic responses post-
ASCT: CR 50%, VGPR 27%, PR 18%, non-response 5%. In all, 85.7% achieved cardiac responses. Median overall survival
(OS) was not reached. Median progression-free survival (PFS) was 54 months. This selected cohort achieved excellent
haematologic responses, organ responses, PFS and OS with deferred ASCT. If larger studies conﬁrm these ﬁndings, this
may widen the applicability of ASCT in AL.
Introduction
Systemic amyloid light chain amyloidosis (AL) is char-
acterised by deposition of misfolded immunoglobulin
light chains within organs, leading to severe visceral
dysfunction. Cardiac involvement is a critical determinant
of survival. High-dose melphalan with autologous stem
cell transplantation (ASCT) in AL can result in high
haematologic response rates, with over a third of patients
achieving complete haematologic response1,2, translating
into promising organ responses3. Response to ASCT
appears to be durable with a median overall survival (OS)
of 7.6 years reported by the Boston group1. Bone marrow
plasma cell inﬁltration >10% prior to ASCT is a poor
prognostic factor4. Transplant-related mortality (TRM)
has historically been high (early reports of up to 40%) in
unselected patients5. The recognition that advanced car-
diac involvement is associated with higher TRM has led to
reﬁned patient selection strategies with a reduction in
TRM to ~5%2 and most recently 2.4% reported by the
Mayo group6. However, stringent selection criteria, which
vary in each country, render the majority of patients with
cardiac amyloidosis transplant-ineligible.
Modern chemotherapy agents can induce haematologic
and organ responses in AL, including those with cardiac
involvement, but durability of response remains uncer-
tain7–9. No study has demonstrated the prolonged
progression-free survival (PFS) patients treated with non-
transplant regimes akin to that achieved with ASCT. It is
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now apparent that a proportion of patients with sig-
niﬁcant cardiac involvement will substantially improve
after achieving a good response to chemotherapy. While
studies have examined the role of bortezomib-based
induction chemotherapy immediately prior to ASCT, no
studies to date have speciﬁcally focussed on the role of
deferred ASCT in transplant-ineligible patients10–13.
We therefore report a retrospective cohort of AL
patients (from two large European amyloidosis centres)
with advanced cardiac involvement who were considered
transplant-ineligible at presentation but achieved hae-
matological and organ responses with chemotherapy,
allowing them to undergo ASCT later.
Methods
All patients with AL ineligible for ASCT at presentation
who had initial induction chemotherapy and then
underwent deferred ASCT from September 2011 to July
2017 were included in this study. Reasons for transplant-
ineligibility are listed in Table 2 and differed slightly
between centres. Amyloidosis of AL type was conﬁrmed
on immunohistochemistry or by proteomic analysis of
biopsy specimens. Exclusion of mutations in genes for
hereditary amyloidosis was carried out as appropriate. All
patients underwent serial protocolised assessment
including biochemical tests for organ function, serum free
light chain measurement, serum and urine protein elec-
trophoresis and immunoﬁxation, cardiac biomarker
assessment, echocardiography and/or cardiac magnetic
resonance imaging (unless contraindicated). Organ
involvement and haematological response were deﬁned as
per international amyloidosis consensus criteria14–16.
Progression was deﬁned as haematologic progression,
time to next treatment or death.
All patients underwent ASCT as per local protocols.
Stem cells were mobilised with granulocyte colony-
stimulating factor only in patients treated at the UK
National Amyloidosis Centre and with cyclophosphamide
priming in the patients at Heidelberg. Transplant con-
ditioning was undertaken with intravenous melphalan,
followed by infusion of autologous haematopoietic stem
cells. Dose reduction of melphalan was used in patients
with severe renal impairment. Standard institutional
protocols were followed for post-transplantation suppor-
tive care and antimicrobial prophylaxis.
Primary outcome variables were TRM (deﬁned as death
within 100 days post-ASCT), haematologic and organ
response, PFS and OS15. Statistical analysis was performed
using SPSS version 24. Approval for analysis and pub-
lication was obtained from the institutional review boards,
and written consent was obtained from all patients in
accordance with the Declaration of Helsinki. Survival
outcomes were analysed using the Kaplan–Meier method.
All p values were two sided with a signiﬁcance level of
<0.05.
Results
Twenty-two patients were included in this study. Nine
were from Heidelberg University Amyloidosis Centre and
13 from the UK National Amyloidosis Centre. Baseline
characteristics are presented in Table 1. The median age
at presentation was 54 years (range 39–69 years). The
number of patients with NYHA class 1, 2, 3 and 4 symp-
toms at presentation was as follows: 1 (4.5%), 17 (77.3%), 3
(13.7%), and 0, respectively. The number of patients with
ECOG score 0, 1, 2, 3 and 4 was: 1 (4.5%), 12 (54.6%), 8
(36.4%), 1 (4.5%), and 0, respectively. The number of
patients with Mayo cardiac stage I, II and III patients were
as follows: 0, 3 (13.6%), and 19 (86.4%), respectively. Of
the stage III patients, 2 patients had an N-terminal pro-
brain natriuretic peptide (NT-proBNP) > 8500 ng/L (stage
IIIb as per the European variation of the original Mayo
staging system17). At diagnosis, median NT-proBNP and
median troponin T were 2924 ng/L (range 624–28737 ng/
L) and 62.5 ng/L (range 9–1885 ng/L), respectively.
Baseline median left ventricular (LV) wall thickness was
15mm (range 8–19mm) and median LV ejection fraction
was 55% (range 38–67%). The number of patients with
renal, liver, soft tissue, peripheral nerve, autonomic nerve
and gastrointestinal involvement was as follows: 8 (36.3%),
4 (18.2%), 9 (40.9%), 2 (9.1%), 2 (9.1%), and 5 (22.7%),
respectively. The median baseline involved free light
chains were 691.5 mg/L (range 135–9594mg/L), with a
median difference in involved and uninvolved light chains
of 562 mg/L (range 118–6830 mg/L).
All patients were regarded as transplant-ineligible at
presentation, most commonly because of advanced, clini-
cally signiﬁcant cardiac involvement (reasons for trans-
plant ineligibility are found in Table 2). All patients were
treated with chemotherapy upfront. All patients had been
treated with bortezomib-based therapy prior to ASCT.
Treatment included bortezomib–dexamethasone in 5
(23%), cyclophosphamide–bortezomib–dexamethasone 13
(59%), bortezomib–lenalidomide–dexamethasone 2 (9%)
and cyclophosphamide–thalidomide–dexamethasone 2
(9%), respectively. Seven (32%) patients switched che-
motherapy after a median of three initial cycles of treat-
ment (range 1–4) due to suboptimal initial haematologic
responses. Of these seven patients, three went on to be
treated with a bortezomib–alkylator–dexamethasone
regime, three went on to be treated with a
bortezomib–immunomodulatory–dexamethasone combi-
nation and one went on to have immunomodulator ther-
apy. The median number of total frontline cycles was 6
(range 4–9). Haematologic responses after chemotherapy
on an intent-to-treat (ITT) basis were: complete haema-
tologic response (CR) 11 (50%), very good partial response
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(VGPR) 8 (36%) and partial response (PR) 3 (14%). At
6 months, 14 patients (64%) achieved a cardiac response,
5/8 (63%) with renal involvement achieved a renal
response and 3/4 (75%) with liver involvement achieved a
liver response14.
The median time from presentation to ASCT was
14.5 months (range 6–45 months). The indication for
ASCT was haematologic progression in 10 (45%) patients
and as a consolidation procedure in the remainder. All
patients had resolution of ASCT exclusion criteria,
enabling them to undergo ASCT (Table 2). There were no
serious adverse events or deaths during stem cell mobi-
lisation. At the time of ASCT, median dFLC (difference
between involved minus uninvolved serum free light
chains) was 25.1 mg/L (range 1.6–911mg/L). At the time
of ASCT, all patients had NYHA class 1–2 symptoms
compared to 81.8% at presentation (p= 0.0013) and
Eastern Cooperative Oncology Group (ECOG) 0–1 prior
to ASCT, compared to 59% of patients with ECOG 0–1 at
presentation (p < 0.0001). The median NT-proBNP prior
Table 1 Baseline characteristics
At presentation At ASCT p Value
Median age (years) 54 (range 39–69) 56 (range 40–70) <0.001
Male:female 15 (68%):7 (32%)
NYHA class
1 1 (4.5%) 13 (59.1%) 0.0013
2 17 (77.3%) 9 (40.9%)
3 3 (13.7%) 0
4 0 0
Not recorded 1 (4.5%) 0
ECOG
0 1 (4.5%) 16 (72.7%) <0.0001
1 12 (54.6%) 6 (27.3%)
2 8 (36.4%) 0
3 1 (4.5%) 0
4 0 0
Cardiac involvement 22 (100%)
Median NT-proBNP (ng/L) 2924 (range 624–28,737) 415 (range 118–2853) <0.0001





(Stage III patients with NT-proBNP > 8500 ng/L) (2 (9.1%))
Median systolic blood pressure (mmHg) 114 (range 80–137) 114 (range 100–142) 0.2107
Median mean left ventricular wall thickness (mm) 15.0 (range 8–19) 14.0 (range 7.5–17.5) 0.0861
Median LV ejection fraction (%) 55 (range 38–67) 57 (range 39–65) 0.285
Renal involvement 8 (36.3%)
Median creatinine (μmol/L) 77 (range 46–537) 80.5 (range 53–162) 0.697
Median GFR (mL/min) 97 (range 10–219) 88 (range 41–124) 0.313
Median proteinuria (g/24 h) 0.35 (range 0.1–4.7) 0.1 (range 0.1–4.1) 0.0356
Liver involvement 4 (18.2%)
Median ALP (units/L) 75.5 (range 42–340) 70.5 (range 40–177) 0.2987
Soft tissue involvement 9 (40.9%)
Peripheral nerve involvement 2 (9.1%)
Autonomic nerve involvement 2 (9.1%)
GI involvement 5 (22.7%)
Median number of involved organs 2 (1–5)
Kappa:lambda 9 (36%):13 (64%)
Median involved FLC (mg/L) 691.5 (range 135–9594) 36.5 (range 0.2–950) <0.0001
Median dFLC (mg/L) 562 (range 118–6830) 25.1 (range 1.6–911) 0.0002
Median serum monoclonal protein (g/L) 1 (range 0–16) 0 (range 0–6) 0.0015
Detectable serum paraprotein 8 (36%) 2 (9%) 0.0011
Serum paraprotein: light chain only/IgG/IgA/IgM/IgD 3 (17%)/5 (23%)/1(5%)/0/0
p values less than 0.05 are found in bold text
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to ASCT was 415 ng/L (range 118–2853 ng/L), having
been 2924 ng/L (624–28,737 ng/L) at presentation (p <
0.0001) and 1497 ng/L (237–5167 ng/L) 6 months after
diagnosis (Fig. 1). The mean LV wall thickness was 15mm
(range 8–19mm), compared to 14mm (range
7.5–17.5 mm) at the time of ASCT (p= 0.086). The
median LV ejection fraction at presentation was 55%
(range 38–67%), compared to 57% (range 39–65%) at the
time of ASCT (p= 0.285). Median cardiac troponin T was
13 ng/L (range 5–76 ng/L), having been 62.5 ng/L (range
9–1885 ng/L) at baseline (p= 0.0142). Median systolic
blood pressure was 114 mmHg (range 80–137) at baseline
and 114 mmHg (range 100–142) at the time of ASCT
(p= 0.21). Median proteinuria had improved from 0.35 g/
24 h (range 0.1–4.7) to 0.1 g/24 h (range 0.1–4.1) at ASCT
(p= 0.036).
Median follow-up was 20.5 months (range
6–74 months). At 3 months post-ASCT, on an ITT basis,
the number of patients in a CR, VGPR, PR and non-
response was: 12 (54.5%), 7 (31.8%), 2(9.1%), and 1 (4.5%).
The patient who had not achieved a haematological
response to ASCT had undergone ASCT for haematolo-
gical progression. The number of patients in a CR, VGPR,
PR and non-response at 6 months post-ASCT on an ITT
basis was: 11 (50%), 6 (27.3%), 4 (18.2%), and 1 (4.5%, died
at 6 months) respectively. Cardiac responses were asses-
sed in 21 patients (the remaining patient died at
6 months). Of these 21 patients, 18 (85.7%) had achieved a
cardiac organ response compared to presentation. Eleven
patients had an NT-proBNP <650 ng/L at the time of
ASCT. Of the remaining ten patients, four patients had a
cardiac response compared to NT-proBNP at the time of
ASCT, four had no cardiac response compared to NT-
proBNP at the time of ASCT and two had evidence of
cardiac progression compared to NT-proBNP at the time
of ASCT. Median NT-proBNP at 6 months post-ASCT
was 554 ng/L (range 186–2589 ng/L) (Fig. 1). The median
dFLC at the time of ASCT in the group who underwent
ASCT for consolidation was 13 mg/L (range 1.6–36mg/
L). In the group who underwent ASCT for relapse, the
median dFLC was 61mg/L (range 24.3–911mg/L), (p=
0.0002).
Table 2 Reasons for transplant ineligibility at presentation
Heidelberg exclusion criteria for ASCT At presentation (n= 9) At ASCT (n= 9)
Severe cardiac failure 6 0
ECOG PS ≥ 2 3 0
Systolic BP ≤ 90 mmHg 2 0
Gastrointestinal bleeding 1 0
UK NAC exclusion criteria for ASCT At presentation (n= 13) At ASCT (n= 13)
NT-proBNP > 1000 ng/L 13 1 (patient had an NT-proBNP response after induction chemotherapy)
Systolic BP ≤ 90 mmHg 1 0
Serum albumin < 20 g/L 1 0
eGFR < 40 ml/min 1 0
Large load on SAP scintigraphy 2 0







































Fig. 1 Serial median NT-proBNP measurements at baseline,
6 months post-diagnosis, prior to ASCT and 6 months post-ASCT
(n= 22). Median NT-proBNP at baseline, 6 months post-diagnosis,
prior to ASCT and 6 months post-ASCT were: 2924 ng/L
(624–28737 ng/L), 1497 ng/L (range 415 ng/L (range 118–2853 ng/L),
415 ng/L (range 118–2853 ng/L), and 554 ng/L (range 186–2589 ng/L),
respectively
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There was no TRM in the cohort. The median OS of
the cohort from time of ASCT has not yet been reached
(Fig. 2). Three patients (13.6%) died (at 6, 11 and
30 months after ASCT). The cause of death in these
patients was: congestive cardiac failure in 2 patients and
chemotherapy-related sepsis (in a patient who developed
haematologic progression 4 months after ASCT). Eight
patients (36%) progressed after ASCT (deﬁned as hae-
matological progression, progression to next treatment or
death). The median PFS in the cohort was 54 months
(Fig. 2). The median OS and median PFS were not
reached in the group who underwent ASCT for
consolidation (Fig. 3). The median OS and median PFS
were 30 months and 11 months, respectively, in the group
who underwent ASCT for haematological progression.
Discussion
ASCT can induce good haematologic and organ
responses in systemic AL amyloidosis, as well as pro-
longed OS1,6. Historically, ASCT in AL has been fraught
with a substantial risk of TRM5 often due to cardiac
involvement, which is a key factor in patient selection2.
However, given that most patients with AL have some
degree of cardiac involvement, upfront ASCT is not a
realistic treatment option for the majority of patients. We
show in this cohort that patients with advanced cardiac
involvement at presentation who were considered
transplant-ineligible can be treated with chemotherapy,
achieving haematological responses that enable improve-
ments in organ function, allowing them to be safely
transplanted at a later date.
ASCT remains an important treatment modality in AL
since none of the standard chemotherapy regimens using
novel agents have shown the prolonged PFS reported with
ASCT. In patients with multiple myeloma, it is clear that
ASCT still has a role in patients treated with novel agent-
based combination regimes and increases the rate of
minimal residual disease negativity, associated with longer
PFS18. Since rigorous patient selection is key to achieving
reduced transplant-related morbidity and mortality in AL,
such selection strategies have become routine in assess-
ment for ASCT. There remains no international con-





Fig. 2 Overall survival (OS) and progression-free survival (PFS)
from time of ASCT. Median OS from ASCT was not reached in the
cohort. Median PFS of the cohort from time of ASCT was 54 months
ASCT for relapse, 
median OS 30 months
ASCT for consolidaon, 
median OS not reached 
ASCT for relapse, 
median PFS 11 months
ASCT for consolidaon, 
median PFS not reached
A B
Fig. 3 Overall survival (OS) and progression-free survival (PFS) in patients undergoing deferred ASCT for relapse or consolidation. a
Median OS in patients who underwent deferred ASCT for consolidation was not reached; patients who underwent deferred ASCT for relapse had a
median OS of 30 months. b Median PFS in patients who underwent for ASCT for consolidation was not reached; patients who underwent deferred
ASCT for relapse had a median PFS of 11 months
Manwani et al. Blood Cancer Journal           (2018) 8:101 Page 5 of 7
Blood Cancer Journal
concur that “signiﬁcant” cardiac involvement is a con-
traindication to transplantation. In our centres, only
10–15% of all patients assessed are considered suitable for
transplantation. Importantly, in this disease, mortality is
concentrated in the early months after diagnosis when
there is ongoing organ damage due to amyloidogenic light
chain toxicity, along with toxicity from treatment regi-
mens and ASCT. Mortality in this disease falls rapidly
after the ﬁrst 6–12 months, hence a deferred transplan-
tation approach is attractive.
Previous studies have examined the role of ASCT later
in the disease course. In the seminal study of 17 patients
treated with bortezomib, cyclophosphamide and dex-
amethasone, Mikhael et al. demonstrated that this treat-
ment regimen rendered three transplant-ineligible
patients to become eligible for ASCT13. Cornell et al. went
on to explore the role of bortezomib-based induction in
28 transplant-ineligible patients with AL11. A third of
patients in the latter study achieved haematologic and
organ responses with bortezomib-based therapy, subse-
quently enabling them to undergo ASCT. However, only
four patients had advanced cardiac involvement that
improved enough to enable transplant eligibility. A single-
centre retrospective cohort study by Hong et al. demon-
strated favourable outcomes in 20 patients treated with
bortezomib-based therapy prior to ASCT, but only 10%
had advanced cardiac involvement12. Similarly, Scott et al.
studied outcomes in 31 patients with AL who underwent
ASCT, of which 12 received bortezomib-based induction
therapy10. The latter authors demonstrated superior
overall haematologic and organ response rates in the
bortezomib pre-treated group. Six patients were initially
deemed transplant-ineligible but became eligible for
ASCT after bortezomib-based therapy but only one
patient had advanced cardiac disease at presentation. In a
recent report of the Mayo group’s 20-year experience of
ASCT in AL, 38% of patients underwent bortezomib-
based treatment before ASCT in 2010–2016, compared to
only 3% from 2003 to 2009. However, only a minority
underwent ASCT >12 months after diagnosis and survival
outcomes in Mayo stage (2012) III/IV cardiac involve-
ment were poorer. It is unclear what proportion of
patients who had deferred transplants had advanced-stage
disease or achieved organ responses with induction che-
motherapy prior to deferred ASCT6.
Unlike previous retrospective cohorts, patients in this
cohort had Mayo stage II/stage III cardiac involvement at
presentation (the majority with stage III involvement).
After induction chemotherapy, 86% achieved a CR/VGPR
and 64% achieved a cardiac response by international
amyloidosis consensus criteria15. Median NT-proBNP fell
from 2924 (624–28,737 ng/L) at presentation to 415 ng/L
(range 118–2853 ng/L) prior to ASCT. ECOG score and
NYHA class improved in the group, with all patients
having ECOG score 0–2 and NYHA class 1–2 symptoms
at ASCT.
Haematological responses 6 months post-ASCT were
excellent, with 77.3% of patients achieving CR/VGPR on
an evaluable basis. These translated into impressive car-
diac organ responses—with 85.7% in a cardiac response
6 months post-ASCT. Despite the majority of patients
having advanced cardiac involvement at presentation,
there was no TRM in the group.
PFS and OS were signiﬁcantly poorer in the group who
underwent ASCT for haematologic progression compared
to those who underwent ASCT as consolidation (Fig. 3).
These ﬁndings are in contrast to an earlier retrospective
study by one of our groups, which suggested that OS and
PFS were not affected by timing of transplantation (i.e.
ASCT at relapse or as consolidation)19. The latter study
included patients from 2003 to 2012 and none of the
patients received a bortezomib-based combination ﬁrst
line (having largely been treated with
cyclophosphamide–thalidomide–dexamethasone or
vincristine–doxorubicin–dexamethasone, compared to
91% patients in this study who received a bortezomib-
based combination ﬁrst line). It is possible that those
patients who relapse having been previously treated with
bortezomib-based therapy have poor risk disease,
accounting for worse outcomes after ASCT compared to
those who are treated for consolidation. Median dFLC at
the time of ASCT were signiﬁcantly higher in the relapse
group compared to the consolidation group, and this may
also account for inferior outcomes in the relapse group.
Larger studies are essential to address the question of
optimal timing of ASCT.
There is another important question of the role of
ASCT in patients who are refractory to ﬁrst-line borte-
zomib-based therapy. Given the relatively conservative
approach to ASCT at our centres, we routinely do not
undertake ASCT in patients who are refractory to therapy.
Such patients proceed to second-line non-ASCT che-
motherapy options to aim for deeper clonal responses.
Seven patients in this cohort did not respond to initial
chemotherapy and switched to second-line treatment
(predominantly with bortezomib-based therapy) and
achieved haematological responses prior to ASCT.
This retrospective small study needs to be interpreted
within its limitations. It features a carefully selected
patient cohort and does not capture ‘all-comers’ to our
centres. Other experienced transplant centres may have
deemed a proportion of patients included in this study to
be suitable for upfront transplants. However, centres with
lesser experience still need to be extremely cautious in
cardiac AL patients due to the risk of TRM.
In conclusion, our data highlight that deferred ASCT
can be undertaken safely in a consolidation or haemato-
logic progression setting in selected patients with
Manwani et al. Blood Cancer Journal           (2018) 8:101 Page 6 of 7
Blood Cancer Journal
advanced cardiac AL who are initially transplant-ineligible
but go on to achieve organ responses. The approach of
novel agent-based chemotherapy followed by deferred
ASCT may allow a greater proportion of patients with
systemic AL amyloidosis to undergo ASCT. Larger studies
with longer follow-up are required to conﬁrm our ﬁnd-
ings, assess durability of response and clarify optimal
timing of ASCT.
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